Health Canada Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes Patients
Health Canada has granted a new indication for Eli Lilly's (LLY) Mounjaro (tirzepatide), allowing its use to reduce the risk of major adverse cardiovascular events. This approval specifically targets individuals living with both type 2 diabetes and established cardiovascular disease. The decision follows positive clinical outcomes from the SURPASS-CVOT trial, which demonstrated the drug's efficacy in mitigating heart-related risks for this patient population. This expansion strengthens Mounjaro's position in the metabolic health market by addressing both glycemic control and long-term cardiovascular complications.

Tickers: $LLY
Topics: cardiovascular disease diabetes drug approval pharmaceuticals
Read the full article at Seeking Alpha
Part of the story Health Canada Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes Patients (2 articles)